3,509 results on '"INFLAMMATORY breast cancer"'
Search Results
2. A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer)
- Published
- 2024
3. CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
- Published
- 2024
4. Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
- Author
-
National Cancer Institute (NCI)
- Published
- 2024
5. A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
- Author
-
Eisai Inc. and Filipa Lynce, MD, Principal Investigator
- Published
- 2024
6. Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy (ConSIBreC)
- Published
- 2024
7. Bicalutamide Enhances Conventional Chemotherapy in In Vitro and In Vivo Assays Using Human and Canine Inflammatory Mammary Cancer Cell Lines.
- Author
-
Crespo, Belen, Illera, Juan Carlos, Silvan, Gema, Lopez-Plaza, Paula, Herrera de la Muela, María, de la Puente Yague, Miriam, Diaz del Arco, Cristina, de Andrés, Paloma Jimena, Illera, Maria Jose, and Caceres, Sara
- Subjects
- *
CELL lines , *CANCER chemotherapy , *CELL migration , *DOCETAXEL , *TUMOR growth , *BREAST , *CANCER cells - Abstract
Human inflammatory breast cancer (IBC) and canine inflammatory mammary cancer (IMC) are highly aggressive neoplastic diseases that share numerous characteristics. In IBC and IMC, chemotherapy produces a limited pathological response and anti-androgen therapies have been of interest for breast cancer treatment. Therefore, the aim was to evaluate the effect of a therapy based on bicalutamide, a non-steroidal anti-androgen, with doxorubicin and docetaxel chemotherapy on cell proliferation, migration, tumor growth, and steroid-hormone secretion. An IMC-TN cell line, IPC-366, and an IBC-TN cell line, SUM149, were used. In vitro assays revealed that SUM149 exhibited greater sensitivity, reducing cell viability and migration with all tested drugs. In contrast, IPC-366 exhibited only significant in vitro reductions with docetaxel as a single agent or in different combinations. Decreased estrogen levels reduced in vitro tumor growth in both IMC and IBC. Curiously, doxorubicin resulted in low efficacy, especially in IMC. In addition, all drugs reduced the tumor volume in IBC and IMC by increasing intratumoral testosterone (T) levels, which have been related with reduced tumor progression. In conclusion, the addition of bicalutamide to doxorubicin and docetaxel combinations may represent a potential treatment for IMC and IBC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Inflammatory breast cancer microenvironment repertoire based on DNA methylation data deconvolution reveals actionable targets to enhance the treatment efficacy
- Author
-
Naiade Calanca, Flavia Lima Costa Faldoni, Cristiano Pádua Souza, Jeferson Santos Souza, Bianca Elen de Souza Alves, Milena Botelho Pereira Soares, Deysi Viviana Tenazoa Wong, Roberto César Pereira Lima-Junior, Fabio Albuquerque Marchi, Claudia Aparecida Rainho, and Silvia Regina Rogatto
- Subjects
Inflammatory breast cancer ,DNA methylation ,Tumor microenvironment ,Endothelial cells ,Immune markers ,Epigenetic silencing ,Medicine - Abstract
Abstract Background Although the clinical signs of inflammatory breast cancer (IBC) resemble acute inflammation, the role played by infiltrating immune and stromal cells in this aggressive disease is uncharted. The tumor microenvironment (TME) presents molecular alterations, such as epimutations, prior to morphological abnormalities. These changes affect the distribution and the intricate communication between the TME components related to cancer prognosis and therapy response. Herein, we explored the global DNA methylation profile of IBC and surrounding tissues to estimate the microenvironment cellular composition and identify epigenetically dysregulated markers. Methods We used the HiTIMED algorithm to deconvolve the bulk DNA methylation data of 24 IBC and six surrounding non-tumoral tissues (SNT) (GSE238092) and determine their cellular composition. The prognostic relevance of cell types infiltrating IBC and their relationship with clinicopathological variables were investigated. CD34 (endothelial cell marker) and CD68 (macrophage marker) immunofluorescence staining was evaluated in an independent set of 17 IBC and 16 non-IBC samples. Results We found lower infiltration of endothelial, stromal, memory B, dendritic, and natural killer cells in IBC than in SNT samples. Higher endothelial cell (EC) and stromal cell content were related to better overall survival. EC proportions positively correlated with memory B and memory CD8+ T infiltration in IBC. Immune and EC markers exhibited distinct DNA methylation profiles between IBC and SNT samples, revealing hypermethylated regions mapped to six genes (CD40, CD34, EMCN, HLA-G, PDPN, and TEK). We identified significantly higher CD34 and CD68 protein expression in IBC compared to non-IBC. Conclusions Our findings underscored cell subsets that distinguished patients with better survival and dysregulated markers potentially actionable through combinations of immunotherapy and epigenetic drugs.
- Published
- 2024
- Full Text
- View/download PDF
9. Refining Local-Regional Therapy for IBC
- Author
-
Faina Nakhlis, MD, Principal Investigator
- Published
- 2023
10. MALE INFLAMMATORY BREAST CANCER-AN ANALYSIS
- Author
-
Alsalamah Ahmed Yasir, Salati Ahmad Sajad, and AlSulaim Sulaiman Lamees
- Subjects
inflammatory breast cancer ,erythema ,metastasis ,mastectomy ,chemotherapy ,hormone therapy ,radiation therapy ,prognosis ,Medicine (General) ,R5-920 - Abstract
Inflammatory breast cancer in males is an uncommon but extremely aggressive form of the disease. It is often misdiagnosed as a benign skin disease since it manifests as erythema along the chest wall. The management guidelines are not specific, and treatment is based on the experiences of female cancer patients. Since there is limited information available about this illness, this review aims to fill that gap by conducting a thorough analysis of case reports published in peer-reviewed journals since 2000.
- Published
- 2024
- Full Text
- View/download PDF
11. Mutational landscape of inflammatory breast cancer
- Author
-
François Bertucci, Florence Lerebours, Michele Ceccarelli, Arnaud Guille, Najeeb Syed, Pascal Finetti, José Adélaïde, Steven Van Laere, Anthony Goncalves, Patrice Viens, Daniel Birnbaum, Emilie Mamessier, Céline Callens, and Davide Bedognetti
- Subjects
Inflammatory breast cancer ,Copy number alteration ,Mutation ,Whole-exome sequencing ,Medicine - Abstract
Abstract Background Inflammatory breast cancer (IBC) is the most pro-metastatic form of BC. Better understanding of its enigmatic pathophysiology is crucial. We report here the largest whole-exome sequencing (WES) study of clinical IBC samples. Methods We retrospectively applied WES to 54 untreated IBC primary tumor samples and matched normal DNA. The comparator samples were 102 stage-matched non-IBC samples from TCGA. We compared the somatic mutational profiles, spectra and signatures, copy number alterations (CNAs), HRD and heterogeneity scores, and frequencies of actionable genomic alterations (AGAs) between IBCs and non-IBCs. The comparisons were adjusted for the molecular subtypes. Results The number of somatic mutations, TMB, and mutational spectra were not different between IBCs and non-IBCs, and no gene was differentially mutated or showed differential frequency of CNAs. Among the COSMIC signatures, only the age-related signature was more frequent in non-IBCs than in IBCs. We also identified in IBCs two new mutational signatures not associated with any environmental exposure, one of them having been previously related to HIF pathway activation. Overall, the HRD score was not different between both groups, but was higher in TN IBCs than TN non-IBCs. IBCs were less frequently classified as heterogeneous according to heterogeneity H-index than non-IBCs (21% vs 33%), and clonal mutations were more frequent and subclonal mutations less frequent in IBCs. More than 50% of patients with IBC harbored at least one high-level of evidence (LOE) AGA (OncoKB LOE 1–2, ESCAT LOE I–II), similarly to patients with non-IBC. Conclusions We provide the largest mutational landscape of IBC. Only a few subtle differences were identified with non-IBCs. The most clinically relevant one was the higher HRD score in TN IBCs than in TN non-IBCs, whereas the most intriguing one was the smaller intratumor heterogeneity of IBCs.
- Published
- 2024
- Full Text
- View/download PDF
12. Lattice radiotherapy in inflammatory breast cancer: report of a first case treated with curative aim.
- Author
-
Parisi, Silvana, Sciacca, Miriam, Critelli, Paola, Ferrantelli, Giacomo, Chillari, Federico, Venuti, Valeria, Napoli, Claudio, Shteiwi, Issa, Siragusa, Carmelo, Brogna, Anna, Pontoriero, Antonio, Ferini, Gianluca, Santacaterina, Anna, and Pergolizzi, Stefano
- Subjects
- *
RADIODERMATITIS , *BREAST cancer , *NEOADJUVANT chemotherapy , *RADIOTHERAPY , *WOMEN patients - Abstract
Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer characterized by poor prognosis. The treatment requires a multidisciplinary approach, with neoadjuvant chemotherapy, surgery, and radiation therapy (RT). Particularly, high doses of conventional RT have been historically delivered in the adjuvant setting after chemotherapy and mastectomy or as radical treatment in patients ineligible for surgery. Here, we report the case of a 49-year-old woman patient with IBC unsuitable for surgery and treated with a combination of lattice RT and fractionated external beam RT concurrent with trastuzumab, with a curative aim. One year after RT, the patient showed a complete response and tolerable toxicities. This is the first reported case of a not-operable IBC patient treated with this particular kind of RT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Current Imaging Approaches in Inflammatory Breast Cancer.
- Author
-
Patel, Miral M., Le-Petross, Huong T., Kapoor, Megha M., Farag, Janet A., Whitman, Gary, and Guirguis, Mary S.
- Abstract
Purpose of Review: Inflammatory breast cancer (IBC) is a rare and aggressive type of breast cancer with a rapid clinical onset and a poor prognosis. The nonspecific clinical criteria have resulted in a difficult and delayed diagnosis of this rare disease. Radiologists' awareness of the appropriate imaging modalities and features of IBC can improve prompt diagnosis, accurate staging of this aggressive disease, and early detection of distant metastases. Recent Findings: Diffuse erythema and severe breast edema involving over one-third of the breast may obscure an identifiable mass on mammography and ultrasound (US) in patients with suspected IBC. Due to utilization of contrast, breast magnetic resonance imaging (MRI) allows exquisite details of breast lesions and is a superior diagnostic modality for IBC. Additionally, breast MRI and Fluorodeoxyglucose positron emission tomography computer tomography (FDG PET-CT) have become standard of care in the staging of IBC patients at the time of presentation. Summary: Clinical presentation combined with mammography, US, and MRI have become standard of care in the diagnosis of IBC. The improved detection and diagnosis using a multimodality approach can contribute towards improved survival. Breast MRI is also beneficial to evaluate treatment response in patients after diagnosis. FDG PET-CT plays a significant role in establishing metastatic disease at the time of initial diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Preoperative Risk Factors for Lymphedema in Inflammatory Breast Cancer.
- Author
-
Copeland-Halperin, Libby R., Hyland, Colby J., Gadiraju, Goutam K., Xiang, David H., Bellon, Jennifer R., Lynce, Filipa, Dey, Tanujit, Troll, Elizabeth P., Ryan, Sean J., Nakhlis, Faina, and Broyles, Justin M.
- Subjects
- *
PREOPERATIVE risk factors , *AXILLARY lymph node dissection , *LYMPHEDEMA , *PATHOLOGY , *BREAST cancer - Abstract
Background Prophylactic lymphatic bypass or LYMPHA (LYmphatic Microsurgical Preventive Healing Approach) is increasingly offered to prevent lymphedema following breast cancer treatment, which develops in up to 47% of patients. Previous studies focused on intraoperative and postoperative lymphedema risk factors, which are often unknown preoperatively when the decision to perform LYMPHA is made. This study aims to identify preoperative lymphedema risk factors in the high-risk inflammatory breast cancer (IBC) population. Methods Retrospective review of our institution's IBC program database was conducted. The primary outcome was self-reported lymphedema development. Multivariable logistic regression analysis was performed to identify preoperative lymphedema risk factors, while controlling for number of lymph nodes removed during axillary lymph node dissection (ALND), number of positive lymph nodes, residual disease on pathology, and need for adjuvant chemotherapy. Results Of 356 patients with IBC, 134 (mean age: 51 years, range: 22–89 years) had complete data. All 134 patients underwent surgery and radiation. Forty-seven percent of all 356 patients (167/356) developed lymphedema. Obesity (body mass index > 30) (odds ratio [OR]: 2.7, confidence interval [CI]: 1.2–6.4, p = 0.02) and non-white race (OR: 4.5, CI: 1.2–23, p = 0.04) were preoperative lymphedema risk factors. Conclusion Patients with IBC are high risk for developing lymphedema due to the need for ALND, radiation, and neoadjuvant chemotherapy. This study also identified non-white race and obesity as risk factors. Larger prospective studies should evaluate potential racial disparities in lymphedema development. Due to the high prevalence of lymphedema, LYMPHA should be considered for all patients with IBC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. CANCERS INFLAMMATOIRES DU SEIN : ASPECTS ÉPIDÉMIOLOGIQUES AU CHU GABRIEL TOUREÀ BAMAKO, MALI.
- Author
-
Kasse, D., Traoré, M., Sidibé, F. M., Tounkara, F. K., Togo, P., and Téguété, I.
- Abstract
Introduction: Inflammatory breast cancer (IBC) is very rare worldwide. The objectives of the present study were to determine the frequency, to describe the socio-demographic and clinical characteristics according to the type of CIS (primary and secondary), and to establish the prognosis. Method: We conducted a retrospective cohort study in the Gynecology-Obstetrics unit of CHU Gabriel Touré (2015 - 2021). Data were analyzed using descriptive statistics and the Kaplan Meier method was used to produce survival curves. Results: We identified 100 cases of IBC among 588 breast cancer cases including 23 cases of primary IBC (3.59%) and 77 cases of secondary IBC (13.1%). The two types of IBC appeared in a relatively younger and peaked between 35 and 40 years old. Contrary to primary IBC, secondary IBC exhibited a second peak between 55 and 60 years old (Wilcoxon rank, test p > 0.05). The time between symptom onset to disease progression was significantly shorter in primary IBC cases versus secondary one (p < 0.001). Overall survival and specific survival according to the type of IBC were less than 40% after 60 months of followed up. Conclusion: The incidence of IBC was high in our setting but dominated by secondary IBC. Whatever the type of IBC, the prognosis was poor. [ABSTRACT FROM AUTHOR]
- Published
- 2024
16. Comprehensive Characterization of Immune Cell Infiltration Characteristics and Drug Sensitivity Analysis in Inflammatory Breast Cancer Based on Bioinformatic Strategy.
- Author
-
Zhang, Zhengguang, Wu, Haitao, Shen, Cunsi, and Zhou, Fuqiong
- Subjects
- *
BREAST cancer , *DRUG analysis , *SENSITIVITY analysis , *GENE expression , *MAST cells , *BREAST - Abstract
Inflammatory breast cancer (IBC) is a rare and highly invasive form of breast cancer, renowned for its aggressive behavior, malignant capacity, and unfavorable prognosis. Despite considerable advancements in comprehending the underlying biology of IBC, the immune cell infiltration (ICI) profile in IBC remains inadequately elucidated. The current work endeavors to investigate the ICI characteristics of IBC and ascertain the pivotal immune cell subtypes and genes that impact its prognosis. The present study employed microarray data from the GEO database to demonstrate that IBC exhibited a lower abundance of activated mast cells (AMC) in comparison to non-inflammatory breast cancer (nIBC) or normal breast tissue (NBT). Additionally, the mRNA expression level of the gene polo-like kinase 5 (PLK5), which was correlated with AMC, was found to be lower in IBC relative to nIBC or NBT. Furthermore, this investigation provided compelling evidence indicating a potential association between a decreased mRNA expression level of PLK5 and a shorter progression-free survival in patients with breast cancer. The gene set enrichment analysis performed on PLK5 revealed that the gene expression in IBC was closely associated with diverse immune functions and pathways. Besides, a negative correlation has been established between PLK5 mRNA expression level and a majority of immune checkpoint-related genes, thereby suggesting the potential suitability of immunotherapy treatment for IBC. In summary, this study offers valuable insights into the ICI profile of IBC and identifies potential target PLK5 for improving its clinical management. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
- Author
-
Nakhlis, Faina, Niman, Samuel M., Ueno, Naoto T., Troll, Elizabeth, Ryan, Sean, Yeh, Eren, Warren, Laura, Bellon, Jennifer, Harrison, Beth, Iwase, Toshiaki, Carisa Le-Petross, H. T., Saleem, Sadia, Teshome, Mediget, Whitman, Gary J., Woodward, Wendy A., Overmoyer, Beth, Tolaney, Sara M., Regan, Meredith, Lynce, Filipa, and Layman, Rachel M.
- Abstract
Purpose: Many stage III inflammatory breast cancer (IBC) patients experience a sufficient response to first-line (1L) neoadjuvant chemotherapy (NAC) to allow surgery, while some require additional NAC. We evaluated the pathologic complete response (pCR), breast cancer-free survival (BCFS) and overall survival (OS) among patients requiring 1 vs. 2-3 lines (L) of NAC prior to surgery. Methods: Stage III IBC patients from 2 institutions who received 1L or 2-3L of NAC prior to surgery were identified. Hormone receptor and HER2 status, grade, and pCR were evaluated. BCFS and OS were evaluated by the Kaplan–Meier method. Multivariable Cox models were utilized to estimate the hazard ratio (HR). Results: 808 eligible patients (1997–2020) were identified (median age 51 years, median follow-up 69 months). 733 (91%) had 1L and 75 (9%) had 2-3L of NAC. Grade III, triple-negative and HER2-positive disease were more prevalent in 2-3L patients. 178 (24%) 1L and 14 (19%) 2-3L patients had pCR. 376 1L patients and 41 2-3L patients had recurrences. The 5-year BCFS was worse for the 2-3L group (33 vs. 46%, HR = 1.37; 95% CI 0.99–1.91). However, in 192 patients with a pCR, BCFS was similar (76 vs. 83% in 1L vs. 2-3L, respectively). There were 308 deaths (276 among 1L and 32 among 2-3L patients). The 5-year OS in 1L vs. 2-3L was 60 vs. 53% (HR = 1.32, 95% CI 0.91–1.93). Conclusions: Among stage III IBC patients, pCR rates were similar, irrespective of the NAC lines number, and BCFS and OS were comparable with pCR after 1L and 2-3L. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Role of CRISPR/Cas9 based therapy in breast cancer: a future direction.
- Author
-
Asrar, Asim, Gupta, Deepika, Sharma, Pooja, Agarwal, Sanjit Kumar, Shukla, Praphulla Chandra, and Bagga, Neha
- Abstract
Breast cancer, a prominent contributor to global cancer-related deaths, is a substantial health obstacle for women. Of all the several types of breast cancers, invasive ductal carcinoma is the most prevalent histological subtype, which includes ductal carcinoma, inflammatory breast cancer, invasive lobular carcinoma, and breast carcinoma. Although there have been improvements in traditional treatment methods, it is still crucial to develop more accurate and efficient therapies. CRISPR technology, which stands for clustered, regularly interspaced short palindromic repeats, has become a ground-breaking tool in the fight against breast cancer. This article provides an overview on the prospective application of CRISPR technology to explore breast cancer and its capacity to transform the identification and therapy of breast carcinoma. Presently, the research community is actively exploring targeted approaches to utilize CRISPR for the purpose of selectively modifying crucial genes linked to breast cancer, surmounting resistance to therapy, and improving the precision of diagnostic methods. Researchers are utilizing the accuracy and CRISPR technology's adaptability to create new tactics & strategies for addressing breast cancer and triple negative breast carcinoma (TNBC), providing renewed optimism for patients and healthcare practitioners. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Delayed Diagnosis of Inflammatory Breast Cancer Presenting as Acute Mastitis in a Patient One Month Postpartum.
- Author
-
Seth, Ananya and Slama, Eliza M.
- Subjects
- *
DELAYED diagnosis , *CANCER diagnosis , *MASTITIS , *TRIPLE-negative breast cancer , *BREAST cancer , *LOBULAR carcinoma , *EDEMA - Abstract
Inflammatory breast cancer (IBC) is a rare yet aggressive form of invasive ductal carcinoma, with a poor prognosis and decreased 5-year survival rates. Characteristic findings for IBC include rapid onset of breast edema, peau d'orange appearance, and involvement of the breast skin. Additionally, diagnosis is confirmed with a skin punch biopsy. With such nonspecific features, IBC can be mistaken for benign etiologies, causing delays in diagnosis and treatment. This patient is a 44-year-old woman presenting with left breast swelling while concurrently breastfeeding. Following antibiotic treatment but no symptom resolution, the patient was referred out for further follow-up. Despite multiple imaging studies, suggesting benign findings, clinical suspicion prompted continued evaluation and finally diagnosis of triple-negative inflammatory breast cancer with distant metastases. Further awareness of the presentation of IBC and its mimicking of other disease processes such as mastitis is paramount to earlier detection and improved outcomes in future patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
- Author
-
Conquer Cancer Foundation and Ayal Aizer, MD, Principal Investigator
- Published
- 2023
21. Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (SHPD002)
- Author
-
Jinsong Lu, professor
- Published
- 2023
22. Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study
- Author
-
Parrish, Kendra M., Thomas, Samantha M., Cartwright, Sara B., van den Bruele, Astrid Botty, Zasloff, Rebecca, DiLalla, Gayle A., DiNome, Maggie L., Menendez, Carolyn S., Rosenberger, Laura H., Woriax, Hannah E., Hwang, E. Shelley, Plichta, Jennifer K., and Chiba, Akiko
- Published
- 2024
- Full Text
- View/download PDF
23. Clipped Axillary Node as a Potential Surrogate for Overall Axillary Nodal Status in Inflammatory Breast Cancer Patients after Neoadjuvant Chemotherapy
- Author
-
Lohani, Kush R., Hoskin, Tanya L., Yasir, Saba, Olson, Carrie A., Boughey, Judy C., Hieken, Tina J., and Degnim, Amy C.
- Published
- 2024
- Full Text
- View/download PDF
24. Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership: Consensus and Opportunities
- Author
-
Glencer, Alexa C., Wanis, Kerollos Nashat, Brown, Sydnee, Lucci, Anthony, Sun, Susie X., Adesoye, Taiwo, DeSnyder, Sarah M., Layman, Rachel, Woodward, Wendy A., Hunt, Kelly K., and Teshome, Mediget
- Published
- 2024
- Full Text
- View/download PDF
25. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer
- Author
-
Filipa Lynce, Laura E. Stevens, Zheqi Li, Jane E. Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M. Force, Tufia C. Haddad, Naoto Ueno, Vered Stearns, Antonio C. Wolff, Amy S. Clark, Jennifer R. Bellon, Edward T. Richardson, Justin M. Balko, Ian E. Krop, Eric P. Winer, Paulina Lange, E. Shelley Hwang, Tari A. King, Sara M. Tolaney, Alastair Thompson, Gaorav P. Gupta, Elizabeth A. Mittendorf, Meredith M. Regan, Beth Overmoyer, and Kornelia Polyak
- Subjects
Inflammatory breast cancer ,Triple negative ,Ruxolitinib ,Paclitaxel ,Neoadjuvant ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Patients with inflammatory breast cancer (IBC) have overall poor clinical outcomes, with triple-negative IBC (TN-IBC) being associated with the worst survival, warranting the investigation of novel therapies. Preclinical studies implied that ruxolitinib (RUX), a JAK1/2 inhibitor, may be an effective therapy for TN-IBC. Methods We conducted a randomized phase II study with nested window-of-opportunity in TN-IBC. Treatment-naïve patients received a 7-day run-in of RUX alone or RUX plus paclitaxel (PAC). After the run-in, those who received RUX alone proceeded to neoadjuvant therapy with either RUX + PAC or PAC alone for 12 weeks; those who had received RUX + PAC continued treatment for 12 weeks. All patients subsequently received 4 cycles of doxorubicin plus cyclophosphamide prior to surgery. Research tumor biopsies were performed at baseline (pre-run-in) and after run-in therapy. Tumors were evaluated for phosphorylated STAT3 (pSTAT3) by immunostaining, and a subset was also analyzed by RNA-seq. The primary endpoint was the percent of pSTAT3-positive pre-run-in tumors that became pSTAT3-negative. Secondary endpoints included pathologic complete response (pCR). Results Overall, 23 patients were enrolled, of whom 21 completed preoperative therapy. Two patients achieved pCR (8.7%). pSTAT3 and IL-6/JAK/STAT3 signaling decreased in post-run-in biopsies of RUX-treated samples, while sustained treatment with RUX + PAC upregulated IL-6/JAK/STAT3 signaling compared to RUX alone. Both treatments decreased GZMB+ T cells implying immune suppression. RUX alone effectively inhibited JAK/STAT3 signaling but its combination with PAC led to incomplete inhibition. The immune suppressive effects of RUX alone and in combination may negate its growth inhibitory effects on cancer cells. Conclusion In summary, the use of RUX in TN-IBC was associated with a decrease in pSTAT3 levels despite lack of clinical benefit. Cancer cell-specific-targeting of JAK2/STAT3 or combinations with immunotherapy may be required for further evaluation of JAK2/STAT3 signaling as a cancer therapeutic target. Trial registration www.clinicaltrials.gov , NCT02876302. Registered 23 August 2016.
- Published
- 2024
- Full Text
- View/download PDF
26. Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
- Author
-
National Cancer Institute (NCI), Rutgers Cancer Institute of New Jersey, and Bruce G Haffty, Professor and Chairman, Department of Radiation Oncology Radiation Oncology
- Published
- 2023
27. Conserving surgery in inflammatory breast cancer after neoadjuvant chemotherapy in patients with clinical complete response: the ConSIBreC randomized controlled trial.
- Author
-
Scardina, Lorenzo, Masetti, Riccardo, and Franceschini, Gianluca
- Subjects
BREAST cancer surgery ,MAGNETIC resonance mammography ,NEOADJUVANT chemotherapy ,AXILLARY lymph node dissection - Abstract
The article provides an overview of the ConSIBreC randomized controlled trial, which aims to evaluate the effectiveness of conserving surgery in patients with inflammatory breast cancer (IBC) who have achieved a clinical complete response after neoadjuvant chemotherapy. IBC is a rare and aggressive subtype of breast cancer, and the standard treatment is radical mastectomy. However, with the increasing rate of complete response to chemotherapy, there is a question of whether breast conserving surgery could be a viable option. The trial will involve 329 patients per arm and will assess local recurrence rates, survival rates, and other outcomes. The study is expected to offer valuable evidence on the potential of conserving surgery in IBC patients. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
28. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
- Author
-
Lynce, Filipa, Stevens, Laura E., Li, Zheqi, Brock, Jane E., Gulvady, Anushree, Huang, Ying, Nakhlis, Faina, Patel, Ashka, Force, Jeremy M., Haddad, Tufia C., Ueno, Naoto, Stearns, Vered, Wolff, Antonio C., Clark, Amy S., Bellon, Jennifer R., Richardson, Edward T., Balko, Justin M., Krop, Ian E., Winer, Eric P., and Lange, Paulina
- Subjects
TRIPLE-negative breast cancer ,PATHOLOGIC complete response ,PACLITAXEL ,RUXOLITINIB ,JAK-STAT pathway - Abstract
Background: Patients with inflammatory breast cancer (IBC) have overall poor clinical outcomes, with triple-negative IBC (TN-IBC) being associated with the worst survival, warranting the investigation of novel therapies. Preclinical studies implied that ruxolitinib (RUX), a JAK1/2 inhibitor, may be an effective therapy for TN-IBC. Methods: We conducted a randomized phase II study with nested window-of-opportunity in TN-IBC. Treatment-naïve patients received a 7-day run-in of RUX alone or RUX plus paclitaxel (PAC). After the run-in, those who received RUX alone proceeded to neoadjuvant therapy with either RUX + PAC or PAC alone for 12 weeks; those who had received RUX + PAC continued treatment for 12 weeks. All patients subsequently received 4 cycles of doxorubicin plus cyclophosphamide prior to surgery. Research tumor biopsies were performed at baseline (pre-run-in) and after run-in therapy. Tumors were evaluated for phosphorylated STAT3 (pSTAT3) by immunostaining, and a subset was also analyzed by RNA-seq. The primary endpoint was the percent of pSTAT3-positive pre-run-in tumors that became pSTAT3-negative. Secondary endpoints included pathologic complete response (pCR). Results: Overall, 23 patients were enrolled, of whom 21 completed preoperative therapy. Two patients achieved pCR (8.7%). pSTAT3 and IL-6/JAK/STAT3 signaling decreased in post-run-in biopsies of RUX-treated samples, while sustained treatment with RUX + PAC upregulated IL-6/JAK/STAT3 signaling compared to RUX alone. Both treatments decreased GZMB
+ T cells implying immune suppression. RUX alone effectively inhibited JAK/STAT3 signaling but its combination with PAC led to incomplete inhibition. The immune suppressive effects of RUX alone and in combination may negate its growth inhibitory effects on cancer cells. Conclusion: In summary, the use of RUX in TN-IBC was associated with a decrease in pSTAT3 levels despite lack of clinical benefit. Cancer cell-specific-targeting of JAK2/STAT3 or combinations with immunotherapy may be required for further evaluation of JAK2/STAT3 signaling as a cancer therapeutic target. Trial registration: www.clinicaltrials.gov, NCT02876302. Registered 23 August 2016. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
29. Bilateral inflammatory recurrence of HER-2 positive breast cancer: a unique case report and literature review.
- Author
-
Rong Qin, Xiangyang Wang, Tingting Fan, Ting Wu, Chao Lu, Xun Shao, and Liang Yin
- Subjects
HER2 positive breast cancer ,LITERATURE reviews ,LOBULAR carcinoma ,METASTATIC breast cancer ,LYMPHADENECTOMY ,MEDICAL research - Abstract
Inflammatory breast cancer (IBC) is an aggressive and rare form of breast cancer with a poor prognosis. The occurrence of bilateral IBC in a short period of time is extremely rare. In this case report, a 54-year-old woman diagnosed with invasive ductal carcinoma of the left breast underwent lumpectomy, lymph node dissection, chemotherapy, and radiotherapy but opted against trastuzumab treatment. Four years later, she experienced bilateral breast inflammation, skin changes, edema, and heat (calor). Biopsies confirmed breast cancer metastasis to both breasts. Whole-Exome Sequencing revealed genetic mutations, including PIK3CA and C4orf54, in both primary and recurrent tumors, with significant downregulation in the recurrent tumors. KEGG analysis suggested potential enrichment of axon guidance signal pathways in both tumors. The patient showed a partial response after treatment with liposome paclitaxel, along with targeted therapy using trastuzumab and pertuzumab. This case report sheds light on the rare occurrence of bilateral inflammatory breast cancer post-HER-2 treatment and highlights the importance of genetic profiling in understanding the disease. Further research on clinical targets for breast cancer management is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Outcomes of Breast-Conserving Therapy in Patients With Inflammatory Breast Cancer: A Meta-Analysis.
- Author
-
Lai, Hui-Ying, Loh, El-Wui, Su, Chih-Ming, Chiang, Meng-Hsuan, and Tam, Ka-Wai
- Subjects
- *
AXILLARY lymph node dissection , *SENTINEL lymph node biopsy , *SENTINEL lymph nodes , *BREAST cancer , *LUMPECTOMY - Abstract
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer. Currently, patients who respond to neoadjuvant chemotherapy (NAC) are treated with mastectomy and axillary lymph node dissection. This study aimed to synthesize real-world data to evaluate the feasibility of breast-conserving therapy (BCT), sentinel lymph node (SLN), and sentinel lymph node biopsy (SLNB) for patients with IBC who respond to NAC. PubMed, Embase, and Cochrane Library databases were searched for relevant articles. Clinical studies that compared mastectomy with BCT for IBC treatment were reviewed. The primary outcomes were local recurrence rate and 5-y survival rate in patients with IBC who responded to NAC. Furthermore, the SLN detection rate and false-negative rate (FNR) for SLNB were also evaluated. In the final analysis, 17 studies were included. The pooled estimates of the local recurrence rate for mastectomy and no surgical intervention were 18.6% and 15.9%, respectively (P = 0.956). Five-y survival was similar for mastectomy, partial mastectomy, and no surgical intervention (45.8%, 57.1%, and 39.4%, respectively). The pooled estimates of the SLN detection rate and FNR for SLNB were 81.9% and 21.8%, respectively. Among patients with IBC who respond to NAC, the local recurrence and 5-y survival rates in those undergoing BCT are noninferior to the rates in those undergoing mastectomy; therefore, BCT could be a feasible option for surgical management. However, a poor SLN detection rate and a high FNR were found in patients undergoing SLNB. Further large-scale clinical studies are required to confirm our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. MALE INFLAMMATORY BREAST CANCER - AN ANALYSIS.
- Author
-
Yasir, Alsalamah Ahmed, Sajad, Salati Ahmad, and Lamees, AlSulaim Sulaiman
- Subjects
BREAST cancer treatment ,CANCER chemotherapy ,CANCER radiotherapy ,CANCER hormone therapy ,MASTECTOMY - Abstract
Copyright of Sanamed is the property of Sanamed and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
32. Bicalutamide Enhances Conventional Chemotherapy in In Vitro and In Vivo Assays Using Human and Canine Inflammatory Mammary Cancer Cell Lines
- Author
-
Belen Crespo, Juan Carlos Illera, Gema Silvan, Paula Lopez-Plaza, María Herrera de la Muela, Miriam de la Puente Yague, Cristina Diaz del Arco, Paloma Jimena de Andrés, Maria Jose Illera, and Sara Caceres
- Subjects
doxorubicin ,docetaxel ,bicalutamide ,inflammatory mammary cancer ,inflammatory breast cancer ,steroid hormones ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Human inflammatory breast cancer (IBC) and canine inflammatory mammary cancer (IMC) are highly aggressive neoplastic diseases that share numerous characteristics. In IBC and IMC, chemotherapy produces a limited pathological response and anti-androgen therapies have been of interest for breast cancer treatment. Therefore, the aim was to evaluate the effect of a therapy based on bicalutamide, a non-steroidal anti-androgen, with doxorubicin and docetaxel chemotherapy on cell proliferation, migration, tumor growth, and steroid-hormone secretion. An IMC-TN cell line, IPC-366, and an IBC-TN cell line, SUM149, were used. In vitro assays revealed that SUM149 exhibited greater sensitivity, reducing cell viability and migration with all tested drugs. In contrast, IPC-366 exhibited only significant in vitro reductions with docetaxel as a single agent or in different combinations. Decreased estrogen levels reduced in vitro tumor growth in both IMC and IBC. Curiously, doxorubicin resulted in low efficacy, especially in IMC. In addition, all drugs reduced the tumor volume in IBC and IMC by increasing intratumoral testosterone (T) levels, which have been related with reduced tumor progression. In conclusion, the addition of bicalutamide to doxorubicin and docetaxel combinations may represent a potential treatment for IMC and IBC.
- Published
- 2024
- Full Text
- View/download PDF
33. Accommodating Time-Varying Heterogeneity in Risk Estimation under the Cox Model: A Transfer Learning Approach.
- Author
-
Li, Ziyi, Shen, Yu, and Ning, Jing
- Subjects
- *
KNOWLEDGE transfer , *PROPORTIONAL hazards models , *MACHINE learning , *ANDERSON model , *HETEROGENEITY , *HAZARD function (Statistics) - Abstract
Transfer learning has attracted increasing attention in recent years for adaptively borrowing information across different data cohorts in various settings. Cancer registries have been widely used in clinical research because of their easy accessibility and large sample size. Our method is motivated by the question of how to use cancer registry data as a complement to improve the estimation precision of individual risks of death for inflammatory breast cancer (IBC) patients at The University of Texas MD Anderson Cancer Center. When transferring information for risk estimation based on the cancer registries (i.e., source cohort) to a single cancer center (i.e., target cohort), time-varying population heterogeneity needs to be appropriately acknowledged. However, there is no literature on how to adaptively transfer knowledge on risk estimation with time-to-event data from the source cohort to the target cohort while adjusting for time-varying differences in event risks between the two sources. Our goal is to address this statistical challenge by developing a transfer learning approach under the Cox proportional hazards model. To allow data-adaptive levels of information borrowing, we impose Lasso penalties on the discrepancies in regression coefficients and baseline hazard functions between the two cohorts, which are jointly solved in the proposed transfer learning algorithm. As shown in the extensive simulation studies, the proposed method yields more precise individualized risk estimation than using the target cohort alone. Meanwhile, our method demonstrates satisfactory robustness against cohort differences compared with the method that directly combines the target and source data in the Cox model. We develop a more accurate risk estimation model for the MD Anderson IBC cohort given various treatment and baseline covariates, while adaptively borrowing information from the National Cancer Database to improve risk assessment. for this article are available online. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Applying a Gene Reversal Rate Computational Methodology to Identify Drugs for a Rare Cancer: Inflammatory Breast Cancer.
- Author
-
Ji, Xiaojia, Williams, Kevin P, and Zheng, Weifan
- Subjects
- *
BREAST cancer , *GENE expression profiling , *ANTINEOPLASTIC agents , *GENE expression , *BREAST , *GENES - Abstract
The aim of this study was to utilize a computational methodology based on Gene Reversal Rate (GRR) scoring to repurpose existing drugs for a rare and understudied cancer: inflammatory breast cancer (IBC). This method uses IBC-related gene expression signatures (GES) and drug-induced gene expression profiles from the LINCS database to calculate a GRR score for each candidate drug, and is based on the idea that a compound that can counteract gene expression changes of a disease may have potential therapeutic applications for that disease. Genes related to IBC with associated differential expression data (265 up-regulated and 122 down-regulated) were collated from PubMed-indexed publications. Drug-induced gene expression profiles were downloaded from the LINCS database and candidate drugs to treat IBC were predicted using their GRR scores. Thirty-two (32) drug perturbations that could potentially reverse the pre-compiled list of 297 IBC genes were obtained using the LINCS Canvas Browser (LCB) analysis. Binary combinations of the 32 perturbations were assessed computationally to identify combined perturbations with the highest GRR scores, and resulted in 131 combinations with GRR greater than 80%, that reverse up to 264 of the 297 genes in the IBC-GES. The top 35 combinations involve 20 unique individual drug perturbations, and 19 potential drug candidates. A comprehensive literature search confirmed 17 of the 19 known drugs as having either anti-cancer or anti-inflammatory activities. AZD-7545, BMS-754807, and nimesulide target known IBC relevant genes: PDK, Met, and COX, respectively. AG-14361, butalbital, and clobenpropit are known to be functionally relevant in DNA damage, cell cycle, and apoptosis, respectively. These findings support the use of the GRR approach to identify drug candidates and potential combination therapies that could be used to treat rare diseases such as IBC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Influence of Macrophages on Vascular Invasion of Inflammatory Breast Cancer Emboli Measured Using an In Vitro Microfluidic Multi-Cellular Platform.
- Author
-
Gadde, Manasa, Mehrabi-Dehdezi, Melika, Debeb, Bisrat G., Woodward, Wendy A., and Rylander, Marissa Nichole
- Subjects
- *
ENDOTHELIAL cells , *IN vitro studies , *COLLAGEN , *CYTOKINES , *INTERLEUKINS , *ENDOTHELIUM , *INFLAMMATION , *CANCER invasiveness , *PERMEABILITY , *STRUCTURAL models , *MACROPHAGES , *MICROFLUIDIC analytical techniques , *EMBOLISMS , *MATRIX metalloproteinases , *RESEARCH funding , *PATHOLOGIC neovascularization , *CELL lines , *EXTRACELLULAR space , *BREAST tumors , *PHENOTYPES - Abstract
Simple Summary: Macrophages, specifically tumor-associated macrophages (TAMs), play a vital role in inflammatory breast cancer (IBC) progression, including cell growth, angiogenesis, and resistance to treatment. Current in vitro models for studying IBC have limitations and do not fully capture the dynamic nature of interactions between macrophages, the tumor, and the microenvironment in IBC. Therefore, we have developed a 3D in vitro model of IBC that incorporates a collagen matrix, functional blood vessels, and THP1 M0, M1, or M2 macrophages, allowing for the study of macrophage-tumor interactions and angiogenesis. Using this platform, it was found that Incorporating TAMs increases the number of new vessel sprouts, permeability of the vessel, matrix porosity, and intravasation of MDA-IBC3 cells. Additionally, IL8 and MMP-9, which are known to promote angiogenesis and tumor invasion, were found to be preferentially secreted in M0 and M2 co-culture platforms. Inflammatory breast cancer (IBC) is an aggressive disease with a poor prognosis and a lack of effective treatments. It is widely established that understanding the interactions between tumor-associated macrophages (TAMs) and the tumor microenvironment is essential for identifying distinct targeting markers that help with prognosis and subsequent development of effective treatments. In this study, we present a 3D in vitro microfluidic IBC platform consisting of THP1 M0, M1, or M2 macrophages, IBC cells, and endothelial cells. The platform comprises a collagen matrix that includes an endothelialized vessel, creating a physiologically relevant environment for cellular interactions. Through the utilization of this platform, it was discovered that the inclusion of tumor-associated macrophages (TAMs) led to an increase in the formation of new blood vessel sprouts and enhanced permeability of the endothelium, regardless of the macrophage phenotype. Interestingly, the platforms containing THP-1 M1 or M2 macrophages exhibited significantly greater porosity in the collagen extracellular matrix (ECM) compared to the platforms containing THP-1 M0 and the MDA-IBC3 cells alone. Cytokine analysis revealed that IL-8 and MMP9 showed selective increases when macrophages were cultured in the platforms. Notably, intravasation of tumor cells into the vessels was observed exclusively in the platform containing MDA-IBC3 and M0 macrophages. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Conserving surgery in inflammatory breast cancer after neoadjuvant chemotherapy in patients with clinical complete response: the ConSIBreC randomized controlled trial
- Author
-
Lorenzo Scardina, Riccardo Masetti, and Gianluca Franceschini
- Subjects
inflammatory breast cancer ,breast conserving surgery ,radical mastectomy ,neoadjuvant chemotherapy ,ConSIBreC trial ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2024
- Full Text
- View/download PDF
37. Breast Reconstruction Use and Impact on Surgical and Oncologic Outcomes Amongst Inflammatory Breast Cancer Patients—A Systematic Review
- Author
-
Ananya Gopika Nair, Gary Tsun Yin Ko, John Laurie Semple, and David Wai Lim
- Subjects
breast reconstruction ,inflammatory breast cancer ,survival ,immediate reconstruction ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Breast reconstruction is generally discouraged in women with inflammatory breast cancer (IBC) due to concerns with recurrence and poor long-term survival. We aim to determine contemporary trends and predictors of breast reconstruction and its impact on oncologic outcomes among women with IBC. A systematic literature review for all studies published up to 15 September 2022 was conducted via MEDLINE, Embase, and the Cochrane Library. Studies comparing women diagnosed with IBC undergoing a mastectomy with or without breast reconstruction were evaluated. The initial search yielded 225 studies, of which nine retrospective cohort studies, reporting 2781 cases of breast reconstruction in 29,058 women with IBC, were included. In the past two decades, immediate reconstruction rates have doubled. Younger age, higher income (>USD 25,000), private insurance, metropolitan residence, and bilateral mastectomy were associated with immediate reconstruction. No significant difference was found in overall survival, breast cancer-specific survival or recurrence rates between women undergoing versus not undergoing (immediate or delayed) reconstruction. There is a paucity of data on delayed breast reconstruction following IBC. Immediate breast reconstruction may be a consideration for select patients with IBC, although prospective data is needed to clarify its safety.
- Published
- 2023
- Full Text
- View/download PDF
38. Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target
- Author
-
François Richard, Maxim De Schepper, Marion Maetens, Sophia Leduc, Edoardo Isnaldi, Tatjana Geukens, Karen Van Baelen, Ha-Linh Nguyen, Peter Vermeulen, Steven Van Laere, François Bertucci, Naoto Ueno, Luc Dirix, Giuseppe Floris, Elia Biganzoli, and Christine Desmedt
- Subjects
Inflammatory breast cancer ,Metastatic breast cancer ,Genomic alterations ,AURKA-Inhibitors ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Inflammatory breast cancer (IBC) is a rare but aggressive subtype of breast cancer, mainly characterized using primary tumor samples. Here, using public datasets, we compared the genomic alterations in primary and metastatic samples from patients with metastatic IBC versus patients with metastatic non-IBC. We observed a higher frequency of AURKA amplification in IBC. We further showed that AURKA amplification was associated with increased AURKA mRNA expression, which we demonstrated was higher in IBC. Finally, higher protein expression of AURKA was associated with worse prognosis in patients with IBC. These findings deserve further investigation given the existence of AURKA-inhibitors.
- Published
- 2023
- Full Text
- View/download PDF
39. Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer
- Author
-
Cvetka Grašič Kuhar, Simona Borštnar, Barbara Gazić, and Erika Matos
- Subjects
Inflammatory breast cancer ,Immunohistochemistry-based subtype ,Pathologic complete response ,Prognostic factors ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Aim: To assess real-world outcomes and prognostic factors of non-metastatic inflammatory breast cancer according to immunohistochemistry (IHC)-based subtype and treatment regimen. Methods: An institutional retrospective analysis of patients treated with neoadjuvant systemic treatment (NAST) for stage III inflammatory breast cancer diagnosed between 2001 and 2018 was performed. The survival outcomes in relation to patient characteristics, tumour characteristics, treatment modality and response to NAST were analyzed. Results: 225 patients fulfilled the inclusion criteria, 90% of patients were node-positive. IHC-based subtypes: 39.1% were HR+/HER2-, 19.1% HR+/HER2+, 23.1% HR-/HER2+ and 18.7% HR-/HER2-. Treatment was multimodal: NAST (100%), surgery (94.2%) and radiotherapy (94.2%). 53.3% of patients received adjuvant endocrine therapy, 34.3% (neo)adjuvant trastuzumab. Tri-modality therapy was applied in 89.3% of patients. Following NAST, a pathologic complete remission (pCR) in the breast was found in 16.9%, in the axilla in 29.7% and in both the breast and axilla in 10.3% of patients. The axillary pCR rate was significantly higher in HR- subtypes. Median overall survival (OS) was 8.9, 7.2, 5.8 and 2.3 years (p
- Published
- 2023
- Full Text
- View/download PDF
40. Inflammatory breast cancer microenvironment repertoire based on DNA methylation data deconvolution reveals actionable targets to enhance the treatment efficacy
- Author
-
Calanca, Naiade, Faldoni, Flavia Lima Costa, Souza, Cristiano Pádua, Souza, Jeferson Santos, de Souza Alves, Bianca Elen, Soares, Milena Botelho Pereira, Wong, Deysi Viviana Tenazoa, Lima-Junior, Roberto César Pereira, Marchi, Fabio Albuquerque, Rainho, Claudia Aparecida, and Rogatto, Silvia Regina
- Published
- 2024
- Full Text
- View/download PDF
41. Mutational landscape of inflammatory breast cancer
- Author
-
Bertucci, François, Lerebours, Florence, Ceccarelli, Michele, Guille, Arnaud, Syed, Najeeb, Finetti, Pascal, Adélaïde, José, Van Laere, Steven, Goncalves, Anthony, Viens, Patrice, Birnbaum, Daniel, Mamessier, Emilie, Callens, Céline, and Bedognetti, Davide
- Published
- 2024
- Full Text
- View/download PDF
42. Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls
- Author
-
Kai CC Johnson, Michael Grimm, Jasmine Sukumar, Patrick M. Schnell, Ko Un Park, Daniel G. Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Robert Wesolowski, Nicole Williams, Sagar Sardesai, Ashley Pariser, Preeti Sudheendra, Gary Tozbikian, Bhuvaneswari Ramaswamy, Dureti Doto, and Mathew A. Cherian
- Subjects
Inflammatory breast cancer ,Overall survival ,Disease-free survival ,Neoadjuvant chemotherapy ,Complete pathological response ,Stage 3 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Inflammatory breast cancer (IBC) poses an ongoing challenge as rates of disease recurrence and mortality remain high compared to stage-matched controls. However, frontline therapy has evolved through the years, including the widespread use of neoadjuvant chemotherapy (NAC) given the prognostic importance of pathologic complete response (pCR). Due to these sweeping changes, we need new data to assess current recurrence and survival outcomes for locally advanced IBC in the context of matched non-inflammatory controls. We conducted a retrospective analysis of institutional IBC data from 2010 to 2016 with the primary objective of comparing overall survival (OS), relapse-free survival (RFS), and distant relapse-free survival (DRFS). We matched IBC patients to non-inflammatory controls based on age, receptor status, tumor grade, clinical stage, and receipt of prior NAC. Secondary objectives included assessing pCR rates and identifying prognostic factors. Among NAC recipients, we observed similar pCR rates (47.6 % vs. 49.4 %, p = 0.88) between IBC (n = 84) and matched non-IBC (n = 81) cohorts. However, we noted a significant worsening of OS (p = 0.0001), RFS (p = 0.0001), and DRFS (p = 0.001) in the IBC group. Specifically, 5-year OS in the IBC cohort was 58.9 % vs. 86.7 % for matched controls (p = 0.0003). Older age was a weak negative predictor for OS (HR 1.03, p = 0.001) and RFS (HR 1.02, p = 0.01). For DRFS, older age was also a weak negative predictor (HR 1.02, p = 0.02), whereas the use of NAC was a positive predictor (HR 0.47, p = 0.02). Despite no clear difference in pCR, survival outcomes remain poor for IBC compared to matched non-inflammatory controls.
- Published
- 2023
- Full Text
- View/download PDF
43. Improved Rate of Negative Margins for Inflammatory Breast Cancer Using Intraoperative Frozen Section Analysis.
- Author
-
Kong, Joshua, Bandyopadhyay, Sudeshna, Chen, Wei, Al-Mufarrej, Faisal, Choi, Lydia, and Kosir, Mary A.
- Subjects
- *
STATISTICS , *INTRAOPERATIVE care , *SURGICAL margin , *FROZEN tissue sections , *TREATMENT effectiveness , *RESEARCH funding , *DESCRIPTIVE statistics , *MASTECTOMY , *ODDS ratio , *BREAST tumors , *RARE diseases , *LONGITUDINAL method - Abstract
Simple Summary: Achieving negative surgical margins following modified radical mastectomy for the treatment of inflammatory breast cancer is critical to the survival of inflammatory breast cancer patients. The current surgical technique is reported to underestimate skin tumor infiltration by up to 60%. The aim of our prospective study was to assess the potential benefit of improving the rate of negative surgical margins for inflammatory breast cancer using intraoperative frozen section analysis. Background: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer with a poor survival rate. Modified radical mastectomy (MRM) with negative pathologic margins is critical for improved survival. We aim to study the potential benefit of intraoperative frozen section analysis (FSA) to improve disease-free margins. Methods: This prospective, monocentric study included 19 patients who underwent MRM for IBC. For each patient, a 2 mm continuous skin edge was sent for FSA to guide further resection. The rate of tumor-free margins and the concurrence between the FSA and permanent pathological results were analyzed. Results: Overall, 15 of the 19 patients achieved negative margins, including four patients who would have had positive margins without FSA. The odds ratio of achieving a negative final margin with FSA was infinity (p = 0.031), and there was a strong agreement between the FSA and permanent pathological results (Kappa—0.83; p < 0.0001). Conclusions: The FSA technique decreased the number of positive margins in IBC patients undergoing MRM, thereby potentially reducing the need for re-operation, allowing immediate wound closure, and preventing delays in the administration of adjuvant radiation therapy. More extensive trials are warranted to establish the use of intraoperative FSA in IBC treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. Racial disparities in treatment and outcomes between non-Hispanic Black and non-Hispanic White women with nonmetastatic inflammatory breast cancer.
- Author
-
Carbajal-Ochoa, Walter H., Johnson, Devin, Alvarez, Alvaro, Bernal, Ana M., and Anampa, Jesus D.
- Abstract
Purpose: The incidence rate of inflammatory breast cancer (IBC) is higher among non-Hispanic Black (NHB) than non-Hispanic White (NHW) women. We examined the differences in treatment and outcomes between NHB and NHW women with IBC, accounting for demographic, clinicopathological, and socioeconomic factors. Methods: We collected data from the Surveillance, Epidemiology, and End Results database for NHB and NHW women with IBC diagnosed between 2010–2016. We analyzed the odds of receiving chemotherapy, radiation, and surgery between NHB and NHW women. We evaluated overall survival (OS) with Kaplan–Meier methods and Cox proportional hazards methods. Competing risk analysis was used to compare the risk of breast cancer death between NHB and NHW women. We also evaluated the magnitude of survival disparities within the strata of demographic, socioeconomic, and treatment factors. Results: Among 1,652 NHW and 371 NHB women with IBC, the odds of receiving chemotherapy, surgery, and radiation were similar for NHB and NHW. After 39-month follow-up, the median OS was 40 and 81 months for NHB and NHW, respectively (p < 0.0001). The risk of breast cancer death was higher for NHB than NHW women (5-year risk of breast cancer death, 51% vs. 35%, p < 0.0001). Conclusion: After adjustment for demographic, clinicopathological, and socioeconomic factors; NHB women with IBC had similar odds of receiving surgery, chemotherapy, and radiation therapy, but were more likely to die of the disease compared to their NHW counterparts. Our findings suggest the presence of masked tumor biology, treatment, or socioeconomic factors associated with race that can lead to worse IBC outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
45. Mastit Tedavi ve İzleminde Radyolojinin Rolü ve Tedavi Edici Girişimsel Yöntemler.
- Author
-
Ayhan, Laçin Tatlı and Gündüz, Yasemin
- Subjects
BREAST cancer ,MASTITIS ,DRAINAGE ,INJECTIONS - Abstract
Copyright of Türk Radyoloji Seminerleri is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
46. Malign Mastit.
- Author
-
Durhan, Gamze
- Subjects
MAGNETIC resonance imaging ,BREAST cancer ,MAMMOGRAMS ,ULTRASONIC imaging ,MASTITIS - Abstract
Copyright of Türk Radyoloji Seminerleri is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
47. Breast Reconstruction Use and Impact on Surgical and Oncologic Outcomes Amongst Inflammatory Breast Cancer Patients—A Systematic Review †.
- Author
-
Nair, Ananya Gopika, Ko, Gary Tsun Yin, Semple, John Laurie, and Lim, David Wai
- Subjects
- *
MAMMAPLASTY , *BREAST cancer , *CANCER patients , *MASTECTOMY , *OVERALL survival - Abstract
Breast reconstruction is generally discouraged in women with inflammatory breast cancer (IBC) due to concerns with recurrence and poor long-term survival. We aim to determine contemporary trends and predictors of breast reconstruction and its impact on oncologic outcomes among women with IBC. A systematic literature review for all studies published up to 15 September 2022 was conducted via MEDLINE, Embase, and the Cochrane Library. Studies comparing women diagnosed with IBC undergoing a mastectomy with or without breast reconstruction were evaluated. The initial search yielded 225 studies, of which nine retrospective cohort studies, reporting 2781 cases of breast reconstruction in 29,058 women with IBC, were included. In the past two decades, immediate reconstruction rates have doubled. Younger age, higher income (>USD 25,000), private insurance, metropolitan residence, and bilateral mastectomy were associated with immediate reconstruction. No significant difference was found in overall survival, breast cancer-specific survival or recurrence rates between women undergoing versus not undergoing (immediate or delayed) reconstruction. There is a paucity of data on delayed breast reconstruction following IBC. Immediate breast reconstruction may be a consideration for select patients with IBC, although prospective data is needed to clarify its safety. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin
- Author
-
Sumito Saeki, Kohei Kumegawa, Yoko Takahashi, Liying Yang, Tomo Osako, Mahmut Yasen, Kazutaka Otsuji, Kenichi Miyata, Kaoru Yamakawa, Jun Suzuka, Yuri Sakimoto, Yukinori Ozaki, Toshimi Takano, Takeshi Sano, Tetsuo Noda, Shinji Ohno, Ryoji Yao, Takayuki Ueno, and Reo Maruyama
- Subjects
Intratumor heterogeneity ,Breast cancer ,Patient-derived organoids ,scRNA-seq ,Cancer cell diversity ,Inflammatory breast cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The intratumor heterogeneity (ITH) of cancer cells plays an important role in breast cancer resistance and recurrence. To develop better therapeutic strategies, it is necessary to understand the molecular mechanisms underlying ITH and their functional significance. Patient-derived organoids (PDOs) have recently been utilized in cancer research. They can also be used to study ITH as cancer cell diversity is thought to be maintained within the organoid line. However, no reports investigated intratumor transcriptomic heterogeneity in organoids derived from patients with breast cancer. This study aimed to investigate transcriptomic ITH in breast cancer PDOs. Methods We established PDO lines from ten patients with breast cancer and performed single-cell transcriptomic analysis. First, we clustered cancer cells for each PDO using the Seurat package. Then, we defined and compared the cluster-specific gene signature (ClustGS) corresponding to each cell cluster in each PDO. Results Cancer cells were clustered into 3–6 cell populations with distinct cellular states in each PDO line. We identified 38 clusters with ClustGS in 10 PDO lines and used Jaccard similarity index to compare the similarity of these signatures. We found that 29 signatures could be categorized into 7 shared meta-ClustGSs, such as those related to the cell cycle or epithelial–mesenchymal transition, and 9 signatures were unique to single PDO lines. These unique cell populations appeared to represent the characteristics of the original tumors derived from patients. Conclusions We confirmed the existence of transcriptomic ITH in breast cancer PDOs. Some cellular states were commonly observed in multiple PDOs, whereas others were specific to single PDO lines. The combination of these shared and unique cellular states formed the ITH of each PDO.
- Published
- 2023
- Full Text
- View/download PDF
49. Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer.
- Author
-
Kuhar, Cvetka Grašič, Borštnar, Simona, Gazić, Barbara, and Matos, Erika
- Subjects
SURVIVAL rate ,PROGNOSIS ,BREAST cancer ,AXILLA ,BREAST cancer prognosis - Abstract
To assess real-world outcomes and prognostic factors of non-metastatic inflammatory breast cancer according to immunohistochemistry (IHC)-based subtype and treatment regimen. An institutional retrospective analysis of patients treated with neoadjuvant systemic treatment (NAST) for stage III inflammatory breast cancer diagnosed between 2001 and 2018 was performed. The survival outcomes in relation to patient characteristics, tumour characteristics, treatment modality and response to NAST were analyzed. 225 patients fulfilled the inclusion criteria, 90% of patients were node-positive. IHC-based subtypes: 39.1% were HR+/HER2-, 19.1% HR+/HER2+, 23.1% HR-/HER2+ and 18.7% HR-/HER2-. Treatment was multimodal: NAST (100%), surgery (94.2%) and radiotherapy (94.2%). 53.3% of patients received adjuvant endocrine therapy, 34.3% (neo)adjuvant trastuzumab. Tri-modality therapy was applied in 89.3% of patients. Following NAST, a pathologic complete remission (pCR) in the breast was found in 16.9%, in the axilla in 29.7% and in both the breast and axilla in 10.3% of patients. The axillary pCR rate was significantly higher in HR- subtypes. Median overall survival (OS) was 8.9, 7.2, 5.8 and 2.3 years (p < 0.001) for HR+/HER2-, HR+/HER2+, HR-/HER2+ and HR-/HER2- subtype, respectively. On multivariate analysis, IHC-based subtype, age and axillary pCR were found as independent prognostic factors for RFS and OS. pCR rate and median OS improved over time, 5.8% vs 14.7% and 4.7 vs 10.0 years (2001–2009 vs. 2010–2018), respectively. Axillary pCR and the non-triple-negative IHC-based subtype are favourable prognostic factors for RFS and OS in inflammatory breast cancer. Introduction of taxanes and antiHER2 drugs contributed to improved pCR rate and OS. • Immunohistochemistry-based subtype is independent prognostic factor for RFS and OS in inflammatory breast cancer. • Axillary pCR is independent prognostic factor for RFS and OS in inflammatory breast cancer. • Axillary pCR is higher in HR-inflammatory breast cancers. • Prognosis of inflammatory breast cancer improved due to more effective systemic therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
50. Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target.
- Author
-
Richard, François, De Schepper, Maxim, Maetens, Marion, Leduc, Sophia, Isnaldi, Edoardo, Geukens, Tatjana, Van Baelen, Karen, Nguyen, Ha-Linh, Vermeulen, Peter, Van Laere, Steven, Bertucci, François, Ueno, Naoto, Dirix, Luc, Floris, Giuseppe, Biganzoli, Elia, and Desmedt, Christine
- Subjects
BREAST cancer ,METASTATIC breast cancer ,METASTASIS ,GENE expression ,PROTEIN expression - Abstract
Inflammatory breast cancer (IBC) is a rare but aggressive subtype of breast cancer, mainly characterized using primary tumor samples. Here, using public datasets, we compared the genomic alterations in primary and metastatic samples from patients with metastatic IBC versus patients with metastatic non-IBC. We observed a higher frequency of AURKA amplification in IBC. We further showed that AURKA amplification was associated with increased AURKA mRNA expression, which we demonstrated was higher in IBC. Finally, higher protein expression of AURKA was associated with worse prognosis in patients with IBC. These findings deserve further investigation given the existence of AURKA-inhibitors. • Inflammatory breast cancer (IBC) is a rare understudied but aggressive type of breast cancer. • AURKA amplification appeared to be more common in patients with metastatic IBC as compared to non-IBC. • AURKA amplification is associated with AURKA expression. • AURKA protein expression is associated with worse prognosis in patients with IBC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.